Xiang Yang No.1 People's Hospital
Institution data
| Type | HEALTHCARE (active) |
|---|---|
| Country | Xiangfan, CN |
| Works | 5 |
| Researchers | 8 |
| Coverage | 2014 - 2025 |
| ROR | 05q9ymz20 |
| GRID | grid.507988.b |
| OpenAlex | I4210164464 |
| Website | http://www.xysdyrmyy.cn |
| Also known as | Xiang Yang No.1 People's Hospital; Xiangyang First People's Hospital; Xiangyang First People's Hospital Affiliated to Hubei Medical College; 襄阳市第一人民医院 |
Global Burden of Disease Study
Personalized smart voice-based electronic prescription for remote at-home feedback management in cardiovascular disease rehabilitation
Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with Covid-19 infection
Anticancer Activity of 5, 7-Dimethoxyflavone Against Liver Cancer Cell Line Hepg2 Involves Apoptosis, Ros Generation and Cell Cycle Arrest
The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients
Global Burden of Disease Study
Personalized smart voice-based electronic prescription for remote at-home feedback management in cardiovascular disease rehabilitation
Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with Covid-19 infection
Anticancer Activity of 5, 7-Dimethoxyflavone Against Liver Cancer Cell Line Hepg2 Involves Apoptosis, Ros Generation and Cell Cycle Arrest
The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients
The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients
Anticancer Activity of 5, 7-Dimethoxyflavone Against Liver Cancer Cell Line Hepg2 Involves Apoptosis, Ros Generation and Cell Cycle Arrest
Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with Covid-19 infection
Personalized smart voice-based electronic prescription for remote at-home feedback management in cardiovascular disease rehabilitation
Global Burden of Disease Study
| ARTICLE | 5 |
|---|
| 2025 | 1 |
|---|---|
| 2023 | 1 |
| 2022 | 1 |
| 2017 | 1 |
| 2014 | 1 |